Veradigm™, an Allscripts (NASDAQ:MDRX), business unit and a leader in providing next-generation healthcare data solutions and systems, is leveraging its capability to communicate directly with a broad network of ambulatory healthcare professionals (HCPs) in order to increase public awareness and access to the Cancer Experience Registry. Developed by the Cancer Support Community's Research and Training Institute, the registry has been a leading communication forum for those impacted by cancer since 2013, enabling patients to share information and their experiences, and supporting empowerment while providing informed patient decision support throughout their cancer journey.
A diagnosis of cancer triggers fear along with a myriad of questions and the need to make a multitude of decisions, for patients, families and HCPs. All cancers are different, and treatment options vary widely not only by type, but may be influenced by geographic location, access to care, insurance coverage, personal financial considerations, and available support systems. Given these complex considerations, the value of self-education and providing a community for cancer patients and families cannot be overstated.
"To show our support for CSC and the millions of Americans whose lives have been touched by cancer, we leveraged Veradigm's ability to reach oncologists within our expansive network of HCPs," said Tom Langan, Veradigm Chief Executive Officer. "In helping to maximize awareness of the Cancer Experience Registry, we can increase the number of Registry participants and amplify the power of the Registry to improve the lives of patients, their families, and care givers living with cancer."
The Cancer Experience Registry provides a mechanism to collect and disseminate critical information designed to allow for informed choices regarding treatment, managing medication adverse reactions, clinical trial opportunities, financial impact consideration, and quality of life. The data collected along with the personal experiences shared by patients, survivors and families through the Cancer Experience Registry brings the cancer closer community together.
CSC and Veradigm were joined in this collaboration by Ogilvy Health, a leading healthcare and wellness marketing and communications agency and an ongoing supporter of CSC.
"Ogilvy Health is very pleased to work with organizations like CSC that are dedicated to improving patients' access to needed therapies, support services and real-world evidence," said Michael Zilligen, Market Access Practice Lead, Ogilvy Health. "We appreciate that Veradigm is providing access to their electronic platform at no cost to CSC, as it is a powerful and proven channel for cancer patients and providers to learn about the registry. In addition to serving patients, the data from the registry provides important insights into challenges patients face in their cancer journey--insights that are essential to all stakeholders, from payers to manufacturers. We are pleased to have played a part in helping to support the mission of the Cancer Experience Registry."
About Allscripts
Allscripts (NASDAQ: MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of HealthTM. Connectivity empowers caregivers to make better decisions and deliver better care for healthier populations.
About Veradigm
Veradigm is an integrated data systems and services business that combines data-driven clinical insights with actionable tools for clinical workflow, research, analytics and media. Our solutions are designed to help key healthcare stakeholders to improve the quality, efficiency, and value of healthcare delivery - from biopharma to health plans, healthcare providers, health technology partners, and most importantly, the patients they serve. We are dedicated to simplifying the complicated healthcare system with next-generation healthcare solutions. That is how we are transforming health, insightfully.